LexBlog IP

DECEMBER 26, 2023

As an update to our previous report , Biocon Biologics Ltd. (a a subsidiary of Biocon Ltd.) a company that develops vaccines using a protein virus-like particle (VLP) platform. The post Biosimilar Deals Updates: Biocon, AstraZeneca appeared first on Big Molecule Watch.

Reporting 52

Reporting Business Intellectual Property 52

LexBlog IP

DECEMBER 2, 2022

As we previously reported , Biocon Biologics Ltd. (a a subsidiary of Biocon Ltd.) This week, Biocon confirmed completion of its acquisition in a part-cash/part-equity transaction. Under the terms of this USD $3.335 billion deal, Biocon paid USD $2 billion up-front in cash, of which $1.2

Business 52

Business Ownership Licensing Reporting 52

LexBlog IP

DECEMBER 21, 2023

10,961,307 (“the ’307 Patent”), directed to methods of treating ulcerative colitis with ustekinumab, Biocon Biologics Inc. Likewise, on December 18, 2023, Biocon filed a petition for IPR of the ‘572 patent, and a motion to join the same proceeding. settled to terminate Samsung Bioepis Co.,

Patent 52

Patent Reporting Settlement Intellectual Property 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

Mylan/Biocon). MYL-14020 (Mylan/Biocon). On August 31, 2020, Biocon Biologics and Mylan announced the launch of Semglee™ (insulin glargine injection), which was approved as an equivalent to Sanofi’s Lantus ® in June 2020 via a New Drug Application (NDA) filed under the Federal Food, Drug, and Cosmetic (FD&C) Act.

Settlement 52

Settlement Litigation Marketing Marketing 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Several other companies have also announced plans to pursue interchangeable status for biosimilar products. Consistent with this, as shown below in Table 2, numerous companies have publicly announced the submission and/or acceptance of new biosimilar BLAs. Semglee ® (Mylan (Viatris) / Biocon). Fulphila ® (Mylan/Biocon).

Litigation 52

Litigation Settlement Patent Marketing 52